Bit Index AI  | Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


Close [ X ]
Copy this code to embed & stream this video on your website
Copy this URL to share or create a link back to this video
Dr. Philipp Hoffmann
Director, Business Development
Daiichi Sankyo/U3 Pharma: development of innovative cancer therapies.
The biotech company U3 Pharma, which belongs to Daiichi Sankyo since 2008, is a source of several new oncology compounds for the Japanese mother company. Most advanced is U3-1287, a anti-HER3 antibody. That could lead to a new cancer drug with high benefits for the patients. With its innovative research and development U3 Pharma contributes to the goal of Daiichi Sankyo to build up a top-ten oncology pipeline till 2015.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
1 2 3 4 of 4   MORE   SHOW
  Select a title or search in slides to skip chapters
, Daiichi Sankyo / U3 Pharma Development of Innovative Cancer Therapies
, Daiichi Sankyo is a truly Global Company
, Oncology is Key in our Global R&D; Focus
, Daiichi Sankyo' s R&D; is organized globally
, U3 Pharma: A German Biotech Success Story
, U3 Pharma has a clear focus on Novel Antibody Drugs in Oncology
, U3-1287 (AMG 888) has important Mode of Actions
, U3-1287 (AMG 888) was successfully tested in Advanced Solid Tumor Patients - Phase 1 Summary
, Phase 1b/2 Study has been initiated in Aug. 2010: Trial Design - 2nd/3rd Line stage IIIb/IV NSCLC
, Advanced/met. NSCLC: Still a highly unmet Medical Need
, U3 Pharma strongly supports our Oncology Pipeline
, Forward-looking Statements